Experimental drug shows promise for rare pancreatic cancer
NCT ID NCT04896073
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 31 times
Summary
This study tested a drug called Minnelide in 16 adults with a rare and aggressive type of pancreatic cancer (ASCP) that had not responded to prior treatments. Participants took Minnelide by mouth for 21 days of each 28-day cycle, for up to 12 cycles. The goal was to see if the drug could shrink or stabilize the cancer. Common side effects were monitored, and the study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOSQUAMOUS CARCINOMA OF THE PANCREAS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.